Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. Overexpression of HER2 was reported in other canc...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| coleção: | Journal of Research in Pharmacy Practice |
| Assuntos: | |
| Acesso em linha: | http://www.jrpp.net/article.asp?issn=2319-9644;year=2016;volume=5;issue=4;spage=227;epage=233;aulast=Moghaddas |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|